Scarica l'app Stockscreener
3.17
0.00%
0.00
Pre-mercato:
3.13
-0.04
-1.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals | 8-K: Current report - Moomoo
Recursion Pharmaceuticals Names New Chief Medical Officer - TipRanks
Recursion appoints Vicki Goodman as Chief Medical Officer; David Mauro to transition to advisor - TradingView
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer - marketscreener.com
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Prolonged Share Price Weakness - Sahm
Recursion Pharmaceuticals Stock (RXRX) Opinions on Roche's AI Drug Development Commitment - Quiver Quantitative
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026 - The Motley Fool
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028 - MarketBeat
Recursion’s Khan: AI will be judged by the medicines it makes - BioCentury
Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors - Yahoo Finance
What makes Recursion Pharmaceuticals (RXRX) so attractive - MSN
Ben Taylor Sells 7,956 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharma CFO Taylor sells $26970 in shares - Investing.com
CFO of Recursion Pharmaceuticals (RXRX) sells 7,956 shares under 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals sets post-hype agenda at LeerinkPartners healthcare event - Traders Union
BofA lowers PT on Recursion Pharmaceuticals (RXRX), keeps a hold rating - MSN
Jim Cramer on Recursion Pharmaceuticals: “It’s a let down, big let down” - MSN
Why Recursion Pharmaceuticals, Inc. (RXRX)'s upside case hasn't fully convinced yet - MSN
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Measuring the AI Bubble - Pharmaceutical Executive
Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down” - Insider Monkey
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress - Sahm
PARG inhibitors disclosed in Recursion Pharmaceuticals patent - BioWorld MedTech
Recursion Pharmaceuticals and Applied Digital shares fall after Nvidia exits stakes - MSN
Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $94,798.30 in Stock - MarketBeat
Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A - Stock Titan
Jim Cramer on Recursion: “It is so low that it comes in under the category of speculative” - MSN
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately - Yahoo Finance
How Recursion’s AI Proof of Concept and Equity Raise Will Impact Recursion Pharmaceuticals (RXRX) Investors - Yahoo Finance
A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results - Yahoo Finance
Recursion’s First AI Clinical Proof Links Pipeline Progress With Valuation Gap - Yahoo Finance
What Makes Recursion Pharmaceuticals (RXRX) So Attractive - Finviz
Recursion rises on new data for asset for polyps - MSN
Najat Khan sells 124,403 Recursion Pharmaceuticals (NASDAQ: RXRX) shares - Stock Titan
Can This AI Stock Bounce Back in 2026? - Yahoo Finance
Day Trade: Why retail investors pile into Recursion Pharmaceuticals Inc. stockTrade Analysis Summary & Community Supported Trade Ideas - Naître et grandir
symbol__ Stock Quote Price and Forecast - CNN
10 Low Risk Penny Stocks to Buy Now - Insider Monkey
Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum - TipRanks
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating - Insider Monkey
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans - Sahm
ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. $RXRX Stake Cut by Amova Asset Management Americas Inc. - MarketBeat
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):